News Releases

email   print   rss   

RSS Feeds

Quest Diagnostics Completes Acquisition of Shiel Medical Laboratory from Fresenius Medical Care
Transaction broadens access to Quest's diagnostic innovations in the New York-New Jersey metropolitan area

SECAUCUS, N.J., Dec. 12, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of the Shiel Medical Laboratory business from Fresenius Medical Care, the premier healthcare company focused on delivering the highest quality care to people with renal and other chronic conditions.

Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

Quest's clinical laboratory in Teterboro, NJ will now provide services previously provided by Shiel in the New York-New Jersey metropolitan area. Patients and providers will benefit from direct access to Quest's broader test menu and an expansive network of Quest Diagnostics patient service centers in the region.

Fresenius Medical Care's dialysis-related laboratory services business, Spectra Labs, was not affected by the transaction.  

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 43,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

50th Anniversary: In 2017, Quest Diagnostics celebrates 50 years of life-changing results. To learn about our legacy of accomplishments and quest to improve healthcare in the future, visit

Quest, Quest Diagnostics, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks are the property of their respective owners.

SOURCE Quest Diagnostics

For further information: Kim Gorode, Quest Diagnostics (Media): 973-520-2800; Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900